New shot aims to stop deadly clots after knee surgery

NCT ID NCT07140523

Recruiting now Disease control Sponsor: Sirius Therapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called SRSD107 to see if it can prevent blood clots in people having knee replacement surgery. About 450 adults aged 60 to 80 will receive either SRSD107 or the standard blood thinner enoxaparin. The goal is to compare how well each drug prevents clots and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SRSD107 (an experimental siRNA drug designed to prevent blood clots)
What this could lead to: If successful, SRSD107 could offer a new way to prevent dangerous blood clots after knee replacement surgery, potentially with fewer injections than current treatments.
What could go wrong: This is an early Phase 2 trial with only 450 participants, so results may not apply to everyone. The drug is still experimental, and its safety and effectiveness compared to enoxaparin are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VENOUS THROMBOEMBOLISM

Contacts and locations

Show contact details

Locations

Hospital Nové Město na Moravě
RECRUITING

Nové Město na Moravě, Czechia

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.